March 2020 Report

March 2020 Report

NEW DRUG AND FIRST TIME GENERIC

New Drug Pipeline

Medication (Trade Name) Drug Class Therapeutic Use Status Update
Rimegepant (Nurtec™ ODT) CGRP Antagonist Migraine Headache Treatment Approved February 27, 2020.
Buprenorphine/Naloxone
(Cassipa®)
Opioid Agonist/Antagonist Opioid Misuse Disorder Launch pending. Approved September 7, 2018.
Benzhydrocodone HCl/
Acetaminophen
(Apadaz™)
Opioid Analgesic –
Immediate Release
Pain Launch pending. Approved February 23, 2018.
Buprenorphine Depot
Injection
(Brixadi™)
Opioid Agonist Treatment of
Opioid Addiction
Anticipated approval December 1, 2020 following
expiration of exclusivity period for Sublocade™.
Celecoxib/Tramadol NSAID/Opioid Agonist Pain FDA review pending.
Eptinezumab CGRP Antagonist Migraine Headache Prevention FDA review pending.
Rimegepant (Zydis®) CGRP Antagonist Migraine Headache Prevention FDA review pending.
Oxycodone HCl (Aximris XR™) Opioid Analgesic –
Extended Release
Pain FDA advisory committee recommended against approval.
Naloxone Injection (Zimhi™) Opioid Antagonist Opioid Overdose FDA declined to approve November 2019.
Oxycodone HCl/
Naltrexone HCl
(SequestOx™)
Opioid Analgesic –
Immediate Release
Pain FDA review pending after declining to approve in 2016.

Generic Pipeline

Medication (Trade Name) Drug Class Therapeutic Use Status Update
Apixaban (Eliquis®) Anticoagulant Treatment/Prophylaxis of Deep Vein Thrombosis Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.
Naloxone HCl
(Narcan®) Nasal Spray
Opioid Antidote Opioid Overdose Launch pending. Generic approved April 19, 2019.
Emtricitabine/Trenofovir
(Truvada®)
Antiretroviral HIV Post-Exposure Prophylaxis Generic anticipated late 2020

Available in the Last 12 Months

Medication (Trade Name) Drug Class Therapeutic Use Status Update
Ubrogepant (Ubrelvy™) CGRP Antagonist Migraine Headache Treatment March 2020
Lasmiditan (Reyvow™) Migraine Agent Migraine Headache Treatment January 2020
Sumatriptan Nasal Spray (Tosymra™) Migraine Agent Migraine Headache Treatment October 2019
Solriamfetol
(Sunosi™)
Stimulant Excessive Sleepiness July 2019
Meloxicam
(Qmiiz™ ODT)
NSAID Pain April 2019
Esketamine Nasal Spray
(Spravato®)
Antidepressant Treatment Resistant Depression March 2019

 

Newly Available Generics

Medication (Trade Name) Drug Class Therapeutic Use Status Update
Naproxen/Esomeprazole (Vimovo®) NSAID/GI Protectant Pain/Stomach Ulcer Prophylaxis February 2020
Albuterol Sulfate (ProAir® HFA) Inhaled Bronchodilator Asthma February 2020
Hydrocodone Bitartrate (Zohydro® ER) Opioid Analgesic – Extended Release Pain January 2020
Doxepin (Silenor®) Tricyclic Antidepressant Sleep Disorders January 2020
Pregabalin
(Lyrica®)
Anticonvulsant Neuropathic Pain July 2019
Cyclobenzaprine HCl
(Amrix®)
Skeletal Muscle Relaxant Muscle Spasm March 2019

Discontinuations

Medication (Trade Name) Drug Class Therapeutic Use Status Update
Morphine Sulfate/Naltrexone HCl (Embeda®) Opioid Analgesic – Extended Release Abuse Deterrent Pain Stop sale date November 15, 2019 with anticipated unavailability early 2020.